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Abstract
Medulloblastoma (MB) is the most common malignant childhood brain tumor. About 30% of all MBs belong to the I
molecular subgroup, characterized by constitutive activation of the Sonic Hedgehog (Hh) pathway. The Hh pathway is
involved in several fundamental processes during embryogenesis and in adult life and its deregulation may lead to
cerebellar tumorigenesis. Indeed, Hh activity must be maintained via a complex network of activating and repressor
signals. One of these repressor signals is KCASH2, belonging to the KCASH family of protein, which acts as negative
regulators of the Hedgehog signaling pathway during cerebellar development and differentiation. KCASH2 leads
HDAC1 to degradation, allowing hyperacetylation and inhibition of transcriptional activity of Gli1, the main effector of
the Hh pathway. In turn, the KCASH2 loss leads to persistent Hh activity and eventually tumorigenesis. In order to
better characterize the physiologic role and modulation mechanisms of KCASH2, we have searched through a
proteomic approach for new KCASH2 interactors, identifying Potassium Channel Tetramerization Domain Containing
15 (KCTD15). KCTD15 is able to directly interact with KCASH2, through its BTB/POZ domain. This interaction leads to
increase KCASH2 stability which implies a reduction of the Hh pathway activity and a reduction of Hh-dependent MB
cells proliferation. Here we report the identification of KCTD15 as a novel player in the complex network of regulatory
proteins, which modulate Hh pathway, this could be a promising new target for therapeutic approach against MB.
Introduction
Medulloblastoma (MB) is the most common malignant
brain tumor in children, representing nearly 20% of all
childhood brain cancers1. Transcriptional and molecular
characterization of MBs has led to their classification into
four primary subgroups: (I) SHH-activated; (II) WNT-
activated; (III) Group 3; and (IV) Group 42–4. Group I
MBs represents about 30% of all MBs and is characterized
by constitutive activation of the Sonic Hedgehog (Hh)
signaling pathway.
The Hh pathway is involved in fundamental processes
during embryogenesis and in adult life, including cell
proliferation, differentiation and morphogenesis, stem cell
maintenance and regeneration5,6, but also in
tumorigenesis.
During cerebellar development, Hh induces the growth
of the external granule layer (EGL), which is mainly
formed by Granule Cell Progenitors (GCPs)7–9. At the
completion of the proliferative stage, Hh signal must be
turned off, GCPs migrate to the cerebellar internal gran-
ule layer (IGL) and differentiate in mature neurons. If the
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Enrico De Smaele (enrico.desmaele@uniroma1.it)
1Department of Molecular Medicine, Sapienza University of Rome, 00161
Rome, Italy
2Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, 00161
Rome, Italy
Full list of author information is available at the end of the article.
These authors contributed equally: Eleonora Spiombi, Annapaola Angrisani
These authors jointly supervised this work: Marta Moretti, Enrico De Smaele
Oncogenesis
12
34
56
78
90
():
,;
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
Hh pathway remains accidentally turned on, it may lead to
cerebellar tumorigenesis10.
Hh signaling pathway is typically initiated by the
expression of Hh secreted ligands, which bind to the
transmembrane receptor Patched1 (Ptch)5. In the absence
of Hh, Ptch represses the other transmembrane receptor
Smoothened (Smo) acting as a negative regulator of the
pathway. In the presence of Hh, Ptch releases Smo which
migrates to the cell primary cilium and leads to the acti-
vation of downstream transcription factors Gli1-35. Non-
canonical activation of the Hh pathway has also been
detected in several tumors, due to ligand-independent
signals, such as K-RAS signaling, TGFβ, PI3K, PKC, and
epigenetic regulators, that act downstream of Smo, lead-
ing to the activation of Glis11,12. These observations,
together with the partial failure of Smo inhibitors in
treatment of a number of Hh-dependent tumors, high-
light the need for therapeutic targeting of the pathway at
the level of Gli transcription factors rather than at the
level of the upstream receptors11.
KCASH2KCTD21 belongs to the family of protein
KCASH (KCTD Containing-Cullin Adaptors, Suppressors
of Hedgehog) and acts as negative regulator of Hh, inhi-
biting Gli transcription factors activity13,14. All three
members of the family (KCASH1, KCASH2 and
KCASH3) can form homo or hetero-oligomers and bind
Cullin3 to form a E3 ubiquitin ligase complex, which
recruits HDAC1 deacetylase inducing its degradation14.
Since HDAC1 deacetylates the transcription factors Gli1
and Gli2 and enhances their transcriptional activity14,15,
degradation of HDAC1 induced by the Cul3/KCASH
complex prevents the activation of Gli1, inhibiting the
Sonic Hedgehog pathway.
Genetic or epigenetic events that reduce the expression
of KCASH family members allow the accumulation of
HDAC1 and consequently the deacetylation of Gli1, that
becomes fully transcriptionally active. Thus, the loss of
KCASH may lead to persistent Hh activity and
tumorigenesis13.
KCASH proteins act in concert to suppress the Hh
pathway. However, the role of these proteins is not
identical. For example, while KCASH1 and KCASH2 bind
directly on HDAC1, KCASH3 cannot do so, but requires
the formation of heterodimers with KCASH1. Indeed,
while the three proteins have somewhat redundant
functions, and share a good degree of homology at the N-
term of the proteins, they may interact with additional
different partners. Furthermore, they present a significant
divergence in the C-terminal halves of the protein, sug-
gesting the presence of peculiar functions or different
mechanisms of individual KCASHs functional regulation.
In order to better characterize the physiologic role and
mechanisms of KCASH2 modulation, we have searched
by means of a proteomic approach for new KCASH2
interactors, identifying Potassium Channel Tetrameriza-
tion Domain Containing 15 (KCTD15).
Here we identify a new role for KCTD15 on Hh pathway
suppression, defining its function as a stabilizer of
KCASH2, which increases its inhibitory activity.
Results
Identification of KCTD15 as a new KCASH2 interactor
To identify potential interactors of KCASH2 we sear-
ched interacting proteins in HEK293T cells transfected
with an expression vector encoding human KCASH2,
N-terminally HA and Flag tagged (Fig. S1A), performing a
sequential double co-immunoprecipitation (Co-IP) of the
cell lysate. The co-immunoprecipitated proteins were
then analyzed by mass spectrometry analysis and poly-
peptides that were represented with a number of peptides
≥3 were selected for further analysis (Fig. S1B).
The most represented interactor was KCTD15.
Similarly to KCASH2, KCTD15 is a member of the
KCTD family of proteins and contains a conserved BTB
domain (characteristic of all the KCTD family members).
Human KCTD15 gene maps to chromosome 19q13.11
and encodes a 283 amino acids (31 KDa) protein.
KCTD15 function has been described mostly in neural
crest16, although other data indicate that it is expressed
also in different adult mouse and human tissues, including
adult brain and cerebellum17–19 suggesting a potential
interplay with KCASH2, which has been described to play
an important role in Hh regulation during cerebellar
development and differentiation13.
To validate the mass spectrometry data, we performed
Co-IP experiments following overexpression of HA-tagged
KCTD15 and Flag-tagged KCASH2 in HEK293T cells, thus
confirming the interaction of the two proteins (Fig. 1a, left
panel). Because of the high homology within the KCASH
proteins and their shared functions, we also evaluated if
KCTD15 interacts with the other KCASH proteins:
KCASH1 and KCASH3. As shown in Fig. 1a (central and
right panels), KCTD15 does not coimmunoprecipitate with
KCASH1 and KCASH3, indicating a specific interaction of
KCTD15 with the KCASH2 family member. We next ver-
ified that KCASH2-KCTD15 interaction does not require
the presence of further adaptor proteins, since a GST pull-
down assay performed with in vitro translated (IVT)
KCTD15 and KCASH2-GST fusion protein indicates that
KCTD15 can bind to GST-KCASH2, while does not bind to
GST alone control (Fig. 1b).
We next investigated whether the two proteins can be
present in the same subcellular compartments. To this
end, we expressed KCTD15 and KCASH2 in the MB cell
line DAOY20 and observed that KCASH2 and KCTD15
indeed colocalize both in the cytoplasm and in the nuclei,
although KCTD15 seems to have a relatively stronger
staining in the nuclei (Fig. S2). This latter observation, in
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which KCASH2 expression does not mirror exactly the
KCTD15 expression, suggests that KCTD15 colocalizes
with KCASH2 but does not sequester or relocate the
KCASH2 protein.
KCTD15 can form homo-oligomeric and hetero-oligomeric
complexes and interacts with KCASH2 through the BTB/
POZ domain
The BTB/POZ domain is a protein-protein interaction
domain involved in oligomerization of many KCTD family
members21. Indeed, the KCASH proteins may form
homo-oligomers and hetero-oligomers through their
BTB/POZ domains13.
Here, by expressing the full-length KCTD15, the BTB-
containing N-terminal half of the protein (BTB-KCTD15)
and the C-terminal half lacking the BTB domain, (called
ΔBTB-KCTD15; see Fig. 2a upper panels) followed by
immunoprecipitation, we demonstrated that KCTD15 is
able to form homo-oligomeric complexes only when the
BTB domain is present, suggesting that BTB is the actual
oligomerization domain (Fig. 2a).
Similarly, we tested if KCTD15 interacts with the BTB
domain of KCASH2. To this purpose, we expressed BTB-
KCASH2 or the KCASH2 C-terminal region (ΔBTB-
KCASH2; see Fig. 2b upper panel) in HEK293T cells.
Following immunoprecipitation assay and Western Blot
analysis, we demonstrated that KCTD15 coimmunopre-
cipitates with the BTB-containing KCASH2 but it does
not with the ΔBTB fragment (Fig. 2b lower panels),
indicating that BTB domains mediate the interaction of
the two proteins.
KCTD15 downregulates Gli1 transcriptional activity and
HDCA1 protein levels but does not bind neither Cul3 nor
HDAC1
Although KCTD15 has been abscribed to a distinct
subgroup of KCTD proteins, it shares a good degree of
similarity in the BTB domain with the KCASH family of
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Fig. 1 KCTD15 interacts specifically with KCASH2. a KCTD15 co-
immunoprecipitates with KCASH2 but not with KCASH1 and KCASH3.
Co-IP assays was performed on total lysates from HEK293T cells
transfected with expression vectors encoding for the indicated
proteins and immunoprecipitated (IP) with anti-Flag agarose beads. IP
samples and a fraction of the total lysate (Total) were separated on
SDS-PAGE gels. Blots were immunoblotted (IB) with anti-KCTD15
antibody and reblotted with anti-Flag antibody. b KCASH2 interacts
with KCTD15 in vitro. IVT KCTD15 was incubated with GST control or
GST-KCASH2. After GST pull-down (see lower panel), the interacting
protein was detected by WB with anti-KCTD15 antibody
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Fig. 2 KCTD15 homo-and hetero-oligomerizes via BTB-POZ
domain. a KCTD15 forms homo-oligomeric complexes via the BTB-
POZ domain. Co-IP experiments performed in lysates from
HEK293T cells cotransfected with expression vectors encoding for the
indicated proteins. IP was performed with anti-Flag conjugated
agarose beads. Blots were IB with anti-HA antibody and reblotted with
anti-Flag antibody. b KCTD15 forms hetero-oligomeric complexes
with KCASH2 via the BTB-POZ domain. Co-IP experiments were
performed as above after co-transfection of vectors expressing
KCTD15-HA or KCASH2 fragments as depicted in the upper panel. IP
was performed with anti-Flag agarose beads, IB with anti-KCTD15
antibody and IP was controlled by reblot with anti-Flag antibody
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proteins22,23. This observation, together with the physical
interaction with KCASH2, suggests that these proteins
might act together and share functional activity.
KCASH2 negatively regulates the Hh signaling, promot-
ing HDAC1 degradation, increasing Gli1 acetylation and
consequently suppressing its transcriptional function13,14.
We investigated whether KCTD15 was able to control
Hh pathway, acting through a similar mechanism. We
performed a preliminary screening on a group of 47
human sporadic MB samples and nine cerebellar controls,
by measuring the expression levels of KCTD15. Interest-
ingly, in a relevant subset of the SHH subgroup (5/19,
26.3% of the samples) there was a marked reduction of
KCTD15 mRNA levels (Fig. S3a), supporting a role for
KCTD15 in Hh context. It has to be noted that among the
other subgroups, only 2/14 samples in Group 3 (which
overall presents higher KCTD15 expression) presented a
KCTD15 reduction.
Analyzing the same samples for the KCASH2 expres-
sion levels, we confirmed that KCASH2 was reduced in
most of SHH MBs, as previously described13 (Fig. S3b). Of
note, we could not find a correlation between expression
levels of KCTD15 and KCASH2 in this context (Fig. S3c),
indicating that KCTD15 is not acting on KCASH2
transcription.
Overexpression of KCTD15 in HEK293T cells sig-
nificantly decreases the transcriptional activity of Gli1-
responsive luciferase reporter (Fig. 3a). To further inves-
tigate KCTD15 mechanism of action, we evaluated if
KCTD15 overexpression acted on Gli1 by affecting the
levels of HDAC1, and indeed observed a significant
reduction of HDAC1 protein (Fig. 3b). Moreover, we
monitored the levels of Gli1 acetylation following
KCTD15 overexpression, confirming that HDAC1
degradation leads also to a decrease in HDAC1 activity
(Fig. 3c).
Next, we wondered if the activity of KCTD15 on
HDAC1 was mediated by the formation of a complex
recruiting Cul3 on HDAC1 or by a different mechanism.
Indeed a previous report, based on data obtained using
recombinant proteins expressed in a bacterial system,
suggested that KCTD15 may be unable to bind Cul323.
By performing a co-immunoprecipitation experiment
with KCTD15, we ruled out an interaction between
KCTD15 and Cul3 or HDAC1 (Fig. 3d, e).
These data suggest an indirect mechanism of action for
KCTD15 on the Hh pathway, and led us to verify if the
action of KCTD15 could be mediated by an effect on
KCASH2.
KCTD15 increases KCASH2 protein stability, thus
enhancing its activity on Gli1
We hypothesized that KCTD15 expression may lead to
an increased KCASH2 protein activity or stability.
Indeed, overexpressed KCTD15 increases the protein
levels of both exogenous (Fig. 4a) and endogenous (Fig.
4b) KCASH2 in HEK293T cells dose-dependent manner,
leading to the hypothesis that its activity on Hh pathway is
an effect of the increase of KCASH2 protein in the cells.
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Fig. 3 KCTD15 reduces Gli1 transcriptional activity and HDAC1
protein levels but does not interact with Cul3 and HDAC1.
a KCTD15 expression reduces Gli1-responsive Luciferase activity.
Assays were performed on lysates from HEK293T cells transfected with
12×-GliRE-Luc alone or with Gli1, KCASH2, KCTD15 and pRL-TK Renilla
(as a normalizer). Data are indicated as mean ratios with respect to
Renilla luciferase signal. *P < 0.05 Gli1 versus control, **P < 0.01
KCASH2 or KCTD15 versus Gli1. b KCTD15 expression reduces HDAC1
protein levels. HEK293T were co-transfected with HDAC1-HA vector,
plus empty or Flag-KCTD15 vectors and protein lysates were analyzed
by WB. c HEK293T were co-transfected with Flag-GLI1 vector plus
empty or KCTD15. IP was performed with anti-Flag conjugated
agarose beads. Blots were IB with anti-acetylated lysine (K518)
antibody and reblotted with anti-Flag antibody (upper panel). Total
lysates were analysed by Western Blot using anti-KCTD15 and anti-
Flag antibodies (lower panel). d, e KCTD15 is not able to interact with
Cul3 (d) and HDAC1 (e). Co-IP experiments are performed in lysates
from HEK293T cells transfected with expression vectors encoding for
the indicated proteins
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We tested this hypothesis by performing a Gli-
responsive luciferase reporter assay in which we co-
transfected different amounts of KCTD15 alone or toge-
ther with a fixed amount of KCASH2 expressing vector.
As shown in Fig. 4c, KCTD15 increases the inhibition of
GliRE-luciferase activity in KCASH2 co-transfected cells
in a dose-dependent manner. Furthermore, KCTD15
alone has an inhibitory effect that can be related to sta-
bilization of the endogenous KCASH2.
To verify if the presence of KCTD15 has a physiolo-
gically relevant function, we monitored the effect of the
depletion of endogenous KCTD15 in HEK293T cells on
a GliRE-luciferase assay. As expected, siRNA-mediated
depletion of endogenous KCTD15 (Fig. 4d, lower panel)
abrogated its stabilizing effect on KCASH2, increasing
the baseline of Gli1 transcriptional levels (See Fig. 4d,
fourth column), and reducing the inhibitory efficiency of
KCASH2 overexpression (Fig. 4d, sixth column). Next,
we confirmed that KCTD15 ability to inhibit Gli1
activity depends on the presence of KCASH2. To this
end, we silenced KCASH2 expression in HEK293T cells
(Fig. S4) and performed in these cells a GliRE-luciferase
assay following overexpression of KCTD15. Indeed,
KCTD15 suppressive activity resulted abolished (Fig.
S5).
KCTD15 expression increases KCASH2 protein levels and
reduces Hh-dependent medulloblastoma cells
proliferation
KCASH2 has been previously shown to suppress
medulloblastoma cell line DAOY growth by negatively
regulating Hh/Gli1 signaling13. To verify the effect of
KCTD15 on this tumor model, we overexpressed
KCTD15 in DAOY cells. As expected, overexpression of
KCTD15 led to an increase of endogenous KCASH2
protein levels (Fig. 5a), and a concomitant reduction in
Hh activity, measured both by monitoring Gli1 protein
levels (Fig. 5a) and expression of Hh target genes, such as
Gli1, N-myc, CyclinD2 (CCND2)24 (Fig. 5b).
Accordingly, colony assays performed on control and
KCTD15 overexpressing DAOY cells demonstrated a
reduced Hh-dependent proliferation (Fig. 5c, d).
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Fig. 4 KCTD15 increases KCASH2 protein levels, enhancing its inhibitory activity on Gli1. a, b Exogenous and endogenous KCASH2 protein
levels increase in presence of KCTD15. a HEK293T cells were transfected with different amounts of Flag tagged KCTD15 and KCASH2 (as indicated),
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Interestingly, not only the absolute number of the
colonies was reduced by 40%, but also the size distribution
of the colonies was affected (Fig. 5e). Indeed, we observed
a marked reduction in the percentages of the medium
(from 19 to 12%) and large (from 1 to 0.5%) colonies in
KCTD15-transfected cells. This suggests that the over-
expression of KCTD15 leads to both a reduced Hh-
dependent stemness of MB cells (which is indicated by a
reduced number of colonies) but also a reduction of the
proliferative potential of the cells, which leads to smaller
colonies. This is consistent with Hh role in tumorigenesis,
which is known to affect both proliferation and cancer cell
stemness6,25,26.
To confirm the anti-proliferative effect of KCTD15 on
DAOY cells, we performed an EdU incorporation assay to
detect and quantify cell proliferation using fluorescence
microscopy. As shown in Fig. 5f and Fig. S6, cells over-
expressing KCTD15 presented a reduced percentage of
EdU positivity. Similar results were obtained using an
MTT assay (Fig. 5g). While FACS analysis of KCTD15
overexpressing cells did not highlight significant altera-
tions in cell cycle (not shown), evaluation of apoptosis
revealed a small but significant difference in the apoptotic
rate of KCTD15-transfected cells (Fig. S7a and S7b).
Apoptosis was detected through DNS assay (Differential
Nuclear Staining)27 and analyzed by fluorescence micro-
scopy, revealing a doubling in apoptotic cells (from 2.5 to
5%) in KCTD15 overexpressing cells (Fig. S7a). Western
Blot analysis for cleaved Caspase3 confirmed this result
(Fig. S7b).
Discussion
Modulation of the Hh signaling pathway is critical for
proper cerebellar development, and aberrant Hh activity
is responsible for a large fraction of all human MB. We
have previously identified a family of Hh suppressors, the
KCASH family, which acts by ubiquitylation and degra-
dation of the HDAC1 deacetylase, leading to Gli1 acet-
ylation and repression of its transcriptional activity.
Here we report the identification of KCTD15 as a novel
player in the complex network of regulatory proteins
which modulate Hh pathway. Indeed, KCTD15 is able to
interact with the Hh inhibitor KCASH2, stabilizing the
protein and enhancing its inhibitory effect in MB cells.
Our preliminary analysis of expression on a group of
MB samples (Supplementary Fig. 3) has suggested that
low levels of KCTD15 may be present in SHH group MB.
Indeed, these results, although suggestive, indicate that
only a subpopulation of SHH medulloblastoma expresses
significantly low KCTD15 mRNA levels. It is possible that
a certain number of MB may express mutated forms of
KCTD15 or have downstream alterations in KCASH2
(loss of expression, mutations) or Hh pathway compo-
nents that render not necessary KCTD15 suppression.
Indeed, statistical analysis performed on a larger group of
samples in publicly available database28 confirmed that,
considering a wider cohort of SHH MB tumors, there is
no significant correlation with KCTD15 expression (not
shown). This may be due in part to the fact that KCTD15
is not a direct modulator of the Hh pathway, but acts
through the modulation of one inhibitor that is KCASH2,
adding complexity and background noise to the analysis.
Furthermore, it is likely that tumors that have already a
significant reduction of KCASH2 expression (KCASH2
low, very frequent in the SHH group), may not be
dependent on a reduction of KCTD15 expression, and
this may lead to loss of statistical relevance of KCTD15
reduction in this group.
It must be considered, furthermore, that KCTD15
action is not through modulation of KCASH2 mRNA
expression, and for this reason it cannot be expected a
positive correlation between KCASH2 and KCTD15
mRNA expression. In fact, in our in vitro experiments, we
never observed any effect of KCTD15 overexpression or
downmodulation on KCASH2 mRNA levels (not shown).
Coherently, we did not find in our SHH MB samples
(and in publicly available databases) a direct correlation
between KCASH2 and KCTD15 mRNA expression
(Supplementary Fig. 3c, R= 0.1, p= 0.69; and not shown).
KCTD15 protein has been previously grouped together
with KCTD1 in a clade of the KCTD family which has
been attributed non-protein degradation functions22. In
fact, KCTD15 does not bind Cul3 and thus does not
appear to be able to directly ubiquitinate and degrade its
protein interactors. Indeed, in our context, interaction of
KCTD15 with KCASH2 leads to KCASH2 protein stabi-
lization, which could be hypothesized to be due to a
conformational change of the oligomer, which may pro-
tect it from faster protein turn-over.
Further work will be needed to explore the conforma-
tions acquired by the KCASH2-KCTD15 oligomers, since
their interaction does not seem to affect negatively the
capability of KCASH2 to bind Cul3 (data not shown) and
definitely does not affect negatively its inhibitory role on
the Hh pathway transcriptional activity.
KCTD15 has been previously credited with transcrip-
tional repression functions22. This has been demonstrated
in vertebrate neural crest during development, in which
KCTD15 has been demonstrated to negatively regulate
the transcription factor TFAP2A, a target of WNT sig-
naling16 by binding to it, changing its conformation and
precluding transcriptional activation16.
KCTD15 function on TFAP2A seems mostly restricted
to neural crest delimitation during the embryonal devel-
opmental phase16. It has also been noted that expression
pattern of TFAP2 and KCTD15 are not largely over-
lapping16 and therefore KCTD15 necessarily plays other
roles in different tissues.
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KCTD15 expression has been previously reported in
adult cerebellum19. Interestingly, most of the cerebellar
cell types (including cerebellar granule neuron, Purkinje
cells, Bergmann Glia, astrocytes) do not derive from
neural crest but from the neural tube, and TFAP2A
expression has been reported to be limited to developing
and adult cerebellar GABAergic interneurons (Purkinje
cells;29). Thus, KCTD15 most probably plays different
functions in cerebellar context, one of whom is the
modulation of KCASH2 in Hh-responsive cells (i.e. cer-
ebellar granule cells).
Here, we demonstrate that KCTD15 contributes to Hh
signaling control, through stabilization of KCASH2.
Indeed, overexpression of KCTD15 in MB cell line DAOY
induces suppression of Hh signaling and reduction of cell
proliferation.
Since modulation of Hh pathway may be also mediated
by effects on Hh pathway proteins trafficking in the pri-
mary cilium, a specialized sub-cellular site that coordi-
nates Hh signal transduction, we verified by
overexpressing tagged proteins in DAOY cells that
KCTD15 and KCASH2 are not localized in the cilium
(Fig. S8).
We hypothesize that loss (or reduction) of KCTD15
expression in cerebellum may lead to a reduced
KCASH2 stability and to an incomplete turn-off of the
Hh pathway, with a consequent increased proliferation of
GCPs, delayed differentiation and tumorigenesis. Inter-
estingly, our preliminary screening on sporadic human
MBs has revealed a marked reduction of KCTD15
expression levels in a subset of the Hh subgroup (Fig. 3a).
Of note, the WNT group expressed high levels of
KCTD15, suggesting the possibility that in this context
KCTD15 may act again by suppressing TFAP2A tran-
scription and consequently its potential WNT/beta-
catenin inhibition30. The identification of this new
function of KCTD15 does not rules out further roles for
KCTD15 in other tissues, since both the presence of the
KCTD domain suggest the potential for further protein-
protein interactions, and the described transcriptional
repression activity may be effective not only on AP2a but
also on other transcription factors.
The new role identified for KCTD15 suggests novel
potential therapeutical approaches for modulating the
Hh pathway in Hh dependent tumors. Indeed, the use of
HDAC inhibitors has been suggest by several group as a
potential therapeutical approach31, alternative to the
resistance-prone Smo inhibitors32 although the spec-
trum of potential HDAC targets in cells does not allow
to exclude unwanted side effects. Up to date there are no
available strategies to positively regulate KCTD15
expression in cancer, though further studies on its
transcriptional modulation may uncover potential
pharmacological modulators. A future strategy may be
to use bioinformatic, proteomic and biochemical
approaches to identify KCTD15/KCASH2 critical
binding sites and generate small peptides or small
molecules that may mimic KCTD15, binding and sta-
bilizing KCASH2. This stabilization would in turn
increase HDAC1 degradation switching off Hh signal-
ing. This approach may be the easiest therapeutical
strategy to implement the KCASH2 inhibitory function
in vivo, given that other strategies such as over-
expression of exogenous KCASH2 in tumor cells may be
more technically challenging.
Materials and methods
Human tissue samples
Human primary MB specimens were collected by
surgical resections with the approval of Sapienza Uni-
versity institutional review board as previously descri-
bed13. Informed consent was obtained from all subjects.
RNAs of normal human cerebella were purchased from
Biocat (Heidelberg, Germany), Ambion (Applied Bio-
systems, Foster City, CA), and BD Biosciences (San
Jose, CA).
Cell Culture, transfections, and luciferase assay
Medulloblastoma cell line DAOY (ATCC HTB-186)
was cultured in minimum essential medium (Gibco-
Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 1% Sodium pyruvate, 1% non-essential amino acid
solution, 1% L-glutamine and 1% penicillin/streptomycin.
DAOY cells were transfected with Lipofectamine Plus,
according to the manufacturer’s instructions (Invitrogen-
Thermo Fisher Scientific). For primary cilium analysis,
cells were kept in low serum (0.5% FBS) 48 h to promote
cilia formation33.
HEK293T cells (ATCC CRL-3216) were cultured in
Dulbecco Modified Eagle Medium (Gibco) supplemented
with 10% FBS, 1% L-glutamine and 1% penicillin/strep-
tomycin. HEK293T cells were transfected with Lipo-
fectamine 2000, according to the manufacturer’s
instructions (Invitrogen).
Mycoplasma contamination in cells cultures was routi-
nely screened by using PCR detection kit (Applied Bio-
logical Materials, Richmond, BC, Canada).
KCTD15 RNA interference (siRNA) was performed
using Silencer® Select Pre-designed siRNA (30 nM;
4392420, Ambion- Thermo Fisher Scientific), transfected
with Lipofectamine 2000 according to the manufacturer’s
instructions.
Luciferase and Renilla activity was assayed with a dual-
luciferase assay system, following manufacturer’s
instructions (Promega, Madison, WI, USA). Results are
expressed as Luciferase/ Renilla ratios and represent the
means ± SD of at least five biological replicates.
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Plasmids
The following vectors, expressing full length or trun-
cated forms of human KCTD15 or KCASHs, with or
without tags: pCDNA3.1-KCTD15; pCXN2-KCTD15,
pCXN2-BTB-KCTD15, pCXN2-ΔBTB-KCTD15, tagged
with Flag or HA; pCXN2-Flag-GLI1, pGEX-KCASH2,
pCDNA3.1-HA-FLAG-KCASH2, pCXN2-KCASH1-Flag,
pCXN2-KCASH3-Flag, pCXN2-KCASH2-Flag, pCXN2-
BTB-KCASH2-Flag, pCXN2-ΔBTB-KCASH2-Flag were
generated in our laboratory with standard cloning tech-
niques and verified by sequencing. pEGFP-N1 was
obtained from Clontech (Takara, Saint-Germain-en-Laye,
France).
The following plasmids were kindly provided by other
laboratories: 12X Gli-Luc and pCMV-SuFu (R. Tofgard,
Karolinska Institutet, Sweden), pCMV-HDAC1 (P.L. Puri,
The Burnham Institute, CA), pCDNA Cul3-myc (M.
Pagano, New York University School of Medicine, NY).
The KCASH2 interference was performed using PLK0.1
plasmid expressing a specific shRNA (Mission shRNA-
TRCN0000139768), and ShC002V as a control (SIGMA).
Lentivirus production and transduction of target cells
Sub confluent HEK293T cells were cotransfected using
Calcium/Phosphate precipitation, with lentiviral con-
structs shKCASH2 and shC002. Viral titers in super-
natants were determined by MOI assay. The
HEK293T cells were transduced with 1 × 106 recombinant
lentivirus-transducing units.
MALDI-TOF mass spectrometry
Sub-confluent HEK293T cells were transfected by
standard Calcium/Phosphate precipitation, with the Flag-
HA-KCASH2 construct described above. Forty-eight
hours after transfection cells were collected and lysed,
then MALDI-TOF mass spectrometry was performed as
previously described34.
RNA isolation and quantitative real-time PCR
Total RNA from cells and tissues samples was extracted
using TRIzol reagent, and cDNA synthesis was performed
using the High Capacity cDNA reverse transcription kit
(Invitrogen) according to the manufacturer’s instructions.
Quantitative real-time PCR analysis of Gli1, N-myc,
cyclin-D2, KCTD15, B-actin, GAPDH, and HPRT mes-
senger RNA (mRNA) was performed on cDNAs
employing using TaqMan gene expression assay accord-
ing to the manufacturer’s instructions (Applied Biosys-
tem- Thermo Fisher Scientific) and using the ViiA™ 7
Real-Time PCR System (Applied Biosystem). Experiments
were replicated biologically at least 3 times, with 3 tech-
nical replicates each. All values were normalized to the
endogenous controls GAPDH, HPRT and B-actin. mRNA
quantification was expressed, in arbitrary units, as the
ratio of the sample quantity to the mean values of control
samples.
Western blot analysis and immunoprecipitation
Cells were lysed with buffer containing: 50 mM Tris-
HCl (pH 7.6), 1% deoxycholic acid sodium salt, 150mM
NaCl, 1% NP40, 5 mM EDTA, 100 mM NaF, and protease
inhibitors. Total protein extracts were then separated on a
denaturing SDS-PAGE gel and evaluated by Western blot
assay using the antibodies listed below. For co-immuno-
precipitation, lysates were incubated with agarose-
conjugated Flag M2 beads (A2220; Sigma Aldrich-
Merck, Darmstadt, Germany) for 2 h at 4 °C. Control
sample antibody was saturated with anti-Flag peptide
(F3290; Sigma). Beads were washed extensively with lysis
buffer, and the complexes were evaluated by Western blot
analysis. Antibody sources were as follows: mouse anti-
tubulin polyclonal (SC-8035; Santa Cruz Biotechnology,
Heidelberg, Germany) and mouse monoclonal anti-beta
actin (A5441; Sigma) goat anti-actin polyclonal (SC-8432;
Santa Cruz Biotechnology); mouse anti-HA monoclonal
(H6533; Sigma), mouse anti-Flag-M2 (A8592; Sigma),
rabbit anti-Myc (A5598; Sigma); rabbit anti-KCTD15
polyclonal antibody (20128-1-AP; Proteintech, Manche-
ster, UK); anti-Gli1 mouse monoclonal (2643; Cell Sig-
naling Technology, Danvers, MA, USA); rabbit anti-
cleaved Caspase3 (9661S; Cell Signaling); rabbit anti-
KCTD21/KCASH2 monoclonal (AB192259; Abcam,
Cambridge, UK) Anti-KCASH2 mouse monoclonal was
generated in house and described in [5]. Anti-acetylated
Gli1 (K518) antibody rabbit polyclonal was previously
described15. Secondary antibody anti–mouse (SC-516102)
/rabbit (SC-2357)/goat IgG (SC-2354) conjugated with
HRP were from Santa Cruz. Blots shown are representa-
tive of at least three independent experiments.
GST pull down assay and in vitro translation
pGEX and pGEX-KCASH2 were expressed in BL-21-
competent bacterial cells. The resultant GST-fusion pro-
teins were purified using a glutathione column. Protein
purity was assessed by SDS-PAGE and Comassie staining.
In vitro translation reactions were performed following the
manufacturer’s instructions (Promega). The reaction mix
contains TNT Rabbit Reticulocyte, TNT Reaction Buffer,
TNT RNA polymerase, Transcent Biotin-Lysyl-tRNA,
amino acid minus methionine, Methionine 1mM, Rnasi-
OUT, and KCTD15-FLAG in PCDNA plasmid. This reac-
tion was incubated at 30 °C for 90min, followed by a
luciferase reaction with standard luciferase assay (Biotium,
CA) and control luciferase DNA (0.5 ug/ul) as a control.
The IVT samples was, then, blotted on membrane and
revealed by Streptavidin-HRP antibody (Promega).
GST-pull down experiment was performed in triplicate
(biological replicates). Briefly, 100 mg of purified
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recombinant GST-KCASH2 was incubated with equal
amount of GST protein in binding buffer (20 mM Hepes
pH 7.9, 150mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.1%
Tween 20 and a cocktail of protease inhibitor and PMSF)
and incubated with 300 μl of glutathione-Sepharose 4B
(Amersham-Sigma) at 4° for 2 h. Then, the beads were
washed five times with the binding buffer, resuspended in
Laemmli sample buffer and boiled. Pulled down proteins
were resolved on SDS-polyacrylamide gels and revealed
by western blot.
Colony assay
DAOY MB cells were transfected as indicated above,
then plated in 10 cm-diameter dishes (1 × 104 cells per
dish) and after 2 weeks of neomycin selection, as pre-
viously described13, cell colonies were fixed and counted
following crystal violet staining in 20% methanol. The
number and size of the colonies were measured using the
ImageJ plugins “colony-counter” (version 1.49v, Java
1.8.0_45, Wayen Rasband, U.S. National Institutes of
Health, Bethesda, MD, USA; website: http://rsb.info.nih.
gov/ij/downl oad.html). The colonies were splitted in
small (range 1–49 points), medium (range 50–99 points),
and large (≥100 points) (1 points= 1 pixel= 0,03 mm).
Experiment was performed in five biological replicates for
each condition.
Proliferation assay
Click-iT™ EdU Alexa Fluor™ 488 Imaging Kit (Life
Technologies, C10337) is optimized to label proliferating
cells, in accordance with manufacturer’s instructions.
For MTT assay, cells were plated at a density of 9,000
cells/well in 96-well plates containing complete medium.
Cell proliferation was detected using CellTiter 96 Aqu-
eous One Solution (Promega) at 24 h following seeding.
For cell proliferation measurement, 20 µl methanethio-
sulfonate reagent was added to the medium and incubated
at 37˚C in a humidified 5% CO2 atmosphere. The
absorbance was read at 490 nm.
Flow cytometry analysis
The cells were harvested, fixed in chilled 70% ethanol,
treated with RNase A (100 μg/ml RNase) for 15 min at
37 °C and stained with propidium iodine (PI) (10 μg/ml
PI) as described35. Data acquisition and analysis was
carried out using a flow cytometry. Data analysis was
performed with CellQuestPro software (BD Biosciences,
Milan, Italy).
Immunofluorescence and DNS assay
DAOY MB cells were cultured on glass coverslips
(chamber 8) and transfected with the indicated plasmids.
After 24 h, cells were fixed, permeabilized and stained, as
described36. Antibodies were as follows: mouse anti-HA
(MMS-101R; Covance, NJ, USA) to identify KCASH2-HA
and rabbit anti-Flag (F7425; Sigma) to identify KCTD15-
Flag; rabbit anti-ARL13B (17711-1-AP, Proteintech,
Rosemont, USA) to stain the cilia. Specific signals were
revealed by AlexaFluor 488 (A11001) and 594 (A21203)
secondary antibodies, respectively (Life Technologies).
The nuclei were counterstained with Hoechst 33342
(U0334; Abnova, Germany). For DNS assay, DAOY cells
were cultured and transfected with indicated plasmids.
After 48 h, cells were incubated with propidium iodide
(10 μM, Sigma P4864, PI) and Hoechst 33342 (10 μM) for
10min, as described27. Images were acquired on a LEICA
DM 2000 microscope.
Statistical analysis
For all luciferase, QPCR, MTT, proliferation, and
apoptotic assays, colony formation assay experiments, the
P values were determined using Student’s t-test and sta-
tistical significance was set at P < 0.05 or P < 0.01. Data
were assumed to have normal distribution. Results are
expressed as mean ± S.D. P values for MB samples was
calculated by Mann Whitney test. All experiments pre-
sented were representative of at least five biological
replicas, except when specifically indicated. Correlation
analysis was measured using GraphPad Prism 6 software
(La Jolla, CA, USA), as previously described37.
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